Vernon Bernardino, an analyst from H.C. Wainwright, reiterated the Buy rating on GeoVax Labs (GOVX – Research Report). The associated ...

As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory ...

BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...

TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

Good morning and welcome to Novavax' Third Quarter 2024 Financial Results and Operational Highlights Conference Call. All ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Novavax Inc (NVAX) reports increased product sales and a strong cash position, while revising revenue guidance and navigating ...

Biotech firm Novavax dropped 9.1% after cutting its annual revenue forecast ... Declining issues outnumbered advancers for a ...

J.P. Morgan analyst Eric Joseph maintained a Sell rating on Novavax (NVAX – Research Report) yesterday and set a price target of $9.00. Eric Joseph has given his Sell rating due to a combination of ...

US stocks were muted on Tuesday as investors were awaiting the key economic data such as inflation and retail sales due later ...

Wall Street's three major indexes closed lower on Tuesday as investors booked some profits from a post-election rally and ...